论文部分内容阅读
目的:观察抗旱2号方治疗女童真性性早熟的疗效,并探讨其作用机制。方法:68例辨证为痰热互结型本病患儿随机分为两组,分别用抗早2号方(治疗组43例)和知柏地黄汤(对照组25例)治疗,并观察患儿临床体征、疗效,测定促卵泡生成素(FSH)、促黄体生成素(LH)、雌二醇(E_2)及子宫卵巢容积、骨龄的变化。结果:临床治疗3个月后,治疗组和对照组总有效率分别为86.0％和76.0％,两组比较差异无显著性(P>0.05)。两组FSH、E_2均较用药前降低(P<0.05),而治疗组FSH、LH降低程度较对照组更显著(P<0.01)。B超显示:治疗组治疗后子宫容积和卵巢容积小于对照组(P<0.05或P<0.01)。用药后6个月骨龄显示:治疗组骨龄增长明显落后于年龄增长,其减缓骨龄增长速度优于对照组(P<0.05)。结论:抗早2号方治疗痰热互结型真性性早熟的疗效确切,是治疗女童真性性早熟的一种有效药物。
Objective: To observe the curative effect of Dankang No.2 decoction on treating girls with precocious puberty and to explore its mechanism. Methods: Sixty-eight children with syndrome of phlegm-heat type were randomly divided into two groups, treated with Kangzao No.2 (treatment group, 43 cases) and Zhibai Dihuang Decoction (control group, 25 cases) The clinical signs, therapeutic effects, determination of follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) and uterine ovarian volume and bone age were measured. Results: After three months of clinical treatment, the total effective rates in the treatment group and the control group were 86.0% and 76.0%, respectively. There was no significant difference between the two groups (P> 0.05). The levels of FSH and E_2 in both groups were lower than those before treatment (P <0.05), while the levels of FSH and LH in treatment group were more significant than those in control group (P <0.01). B-ultrasound showed that the uterine volume and ovarian volume in the treatment group were less than those in the control group (P <0.05 or P <0.01). Bone age at 6 months after treatment showed that the bone age of the treatment group lagged behind that of the aging group, and its bone growth retardation rate was better than that of the control group (P <0.05). Conclusion: Kangzao 2 Prescription is effective in treating true sexual precocity of phlegm-heat interaction and is an effective drug for treating the girl’s sexual precocity.